Document Detail


Technology evolution: is it survival of the fittest?
MedLine Citation:
PMID:  20697074     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
New technologies are constantly being developed and introduced into medical practice. Their potential or actual use raises questions of efficacy and cost. All too often financial considerations of profit primarily determine whether a technology will be adopted. In an era in which the need to control costs has become clear, this situation is undesirable. The assessment of efficacy can, however, be very difficult, and the control of financial aspects is likewise problematic. In this article, we address these problems and suggest potential solutions, using proton radiotherapy as an example that may be relevant to the development of other medical devices.
Authors:
Anthony Zietman; Michael Goitein; Joel E Tepper
Related Documents :
15966144 - How to select a sterilisation process.
1634264 - The impact of standards.
2834214 - Paranormal health claims.
3638344 - Intrauterine treatment of fetal tachycardia.
6417254 - Risk acceptance criteria and their development.
1641534 - Medical laboratory technologists' perception of professional self. a study of swedish m...
Publication Detail:
Type:  Journal Article     Date:  2010-08-09
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  28     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2010 Sep 
Date Detail:
Created Date:  2010-09-17     Completed Date:  2010-10-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  4275-9     Citation Subset:  IM    
Affiliation:
Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Clinical Trials as Topic
Cost Control
Diffusion of Innovation*
Equipment Design
Evidence-Based Medicine
Health Care Costs
Humans
Patient Selection
Protons / therapeutic use*
Radiotherapy / economics,  instrumentation*
Technology Transfer*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Protons

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Active Surveillance: Is There a Need for Better Risk Stratification at the Outset?
Next Document:  Reply to P. Singh et al.